Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells. The programmed death 1 (PD-1) pathway dampens immune responses to tumor cells, and several clinical trials have shown favorable outcomes by targeting PD-1 or its ligand PD-1L.

In this issue of JCI Insight, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology examined PD-1-expressing regulatory T cells in glioblastoma multiforme, an extremely aggressive form of brain cancer. Regulatory T cells normally constrain immune responses and keep other types of T cells from mounting hyper-aggressive responses.

Although anti-PD1 therapy is generally thought to promote conventional T cell activity, the Hafler team now reports that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.

They also found that glioblastoma multiforme patients treated with a PD-1 blocking antibody had a higher proportion of dysfunctional regulatory T cells. These observations suggest the possibility that PD-1 targeting therapies could work, in part, by driving further regulatory T .

Future studies will be needed to more fully understand the contribution of this pathway to anti-tumor effects.


Explore further

Histone deacetylase inhibitors enhance immunotherapy in lung cancer models, researchers say

More information: Daniel E. Lowther et al, PD-1 marks dysfunctional regulatory T cells in malignant gliomas, JCI Insight (2016). DOI: 10.1172/jci.insight.85935
Citation: Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer (2016, April 21) retrieved 17 October 2019 from https://medicalxpress.com/news/2016-04-critical-immunotherapy-dysfunctional-regulatory-cells.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more